Literature DB >> 10795374

Facilitative glucose transporter expression in human cancer tissue.

T A Smith1.   

Abstract

Glucose utilisation by cancer cells is greatly enhanced when compared with that by normal tissue. Glucose is taken up by cells and then phosphorylated to glucose-6-phosphate. Facilitative hexose uptake is achieved by five transmembrane transporters, termed glut1-5, which are protein products of their respective GLUT genes. Glut types differ in their kinetics, which are tailored to the requirements of the cell type they serve, although more than one glut may be expressed by a particular cell type. Herein are reviewed the results from approximately 30 studies which examined glut expression in human cancer tissue. These studies measured GLUT messenger RNA (mRNA) either using the reverse-transcriptase polymerase chain reaction or by Northern blot analysis, or detected glut proteins using the appropriate antibodies. Tumour tissue is frequently associated with the abnormal and/or over-expression of gluts, especially glut1. Some tumour cells express specific GLUT mRNA but not the respective protein. Some studies have reported associations between glut expression and proliferative indices, whilst others suggest that glut may be of prognostic significance, especially in lung cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10795374

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  34 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

3.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

4.  Overexpression of tumor suppressor protein OSCP1/NOR1 induces ER stress and apoptosis during development of Drosophila melanogaster.

Authors:  Nguyen Tho Huu; Hideki Yoshida; Masamitsu Yamaguchi
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

5.  Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.

Authors:  Hans-Richard Demel; Benedikt Feuerecker; Guido Piontek; Christof Seidl; Birgit Blechert; Anja Pickhard; Markus Essler
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 6.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

7.  Glucose-6-phosphatase Expression-Mediated [18F]FDG Efflux in Murine Inflammation and Cancer Models.

Authors:  Mi Jeong Kim; Chul-Hee Lee; Youngeun Lee; Hyewon Youn; Keon Wook Kang; JoonHo Kwon; Abass Alavi; Sean Carlin; Gi Jeong Cheon; June-Key Chung
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

8.  Diabetes mellitus and hyperglycemia are associated with inferior oncologic outcomes in adrenocortical carcinoma.

Authors:  Sean M Wrenn; T K Pandian; Rajshri M Gartland; Zhi Ven Fong; Matthew A Nehs
Journal:  Langenbecks Arch Surg       Date:  2021-02-01       Impact factor: 3.445

9.  Prediction of mediastinal lymph node metastasis based on 18F-FDG PET/CT imaging using support vector machine in non-small cell lung cancer.

Authors:  Guotao Yin; Yingchao Song; Xiaofeng Li; Lei Zhu; Qian Su; Dong Dai; Wengui Xu
Journal:  Eur Radiol       Date:  2020-11-17       Impact factor: 5.315

Review 10.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.